11/20
09:01 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
11/20
08:44 am
mdgl
Rating for MDGL
Low
Report
Rating for MDGL
11/1
02:26 pm
mdgl
Rating for MDGL
Medium
Report
Rating for MDGL
10/23
08:23 am
mdgl
Rating for MDGL
Low
Report
Rating for MDGL
10/23
08:23 am
mdgl
Rating for MDGL
Low
Report
Rating for MDGL
10/22
08:32 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $390.00 price target on the stock.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $390.00 price target on the stock.
10/11
01:49 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
10/11
01:07 pm
mdgl
Rating for MDGL
Low
Report
Rating for MDGL